OncoMatch/Clinical Trials/NCT05969041
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
Is NCT05969041 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MT-302 (A) for epithelial tumors, malignant.
Treatment: MT-302 (A) — MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Histologically proven, metastatic or advanced epithelial cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate organ function as defined by laboratory values at Screening
Kidney function
Adequate organ function as defined by laboratory values at Screening
Liver function
Adequate organ function as defined by laboratory values at Screening
Cardiac function
Ejection fraction ≥ 50% by ECHO or MUGA; ECG showing no clinically significant abnormality or QTc < 450 msec (males), < 470 msec (females), < 480 msec (bundle branch block)
Echocardiogram (ECHO) or multiple gated acquisition scan showing an ejection fraction greater than or equal to 50%. Electrocardiogram (ECG) showing no clinically significant abnormality at Screening or showing an average QTc interval < 450 msec in males and < 470 msec in females (< 480 msec for participants with bundle branch block). Adequate organ function as defined by laboratory values at Screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify